showed that CIS samples had a 46-gene expression signature in which the druggable targets MTOR, TYK2, AXIN1, CTP1B, GAK, and PIEZO1 were selectively upregulated while BRD2 and NDUFB2 were selectively downregulated (107). Here, GAK is linked to in situ carcinoma.